Cargando…

Determinants of Use of Intermittent Preventive Treatment of Malaria in Pregnancy: Jinja, Uganda

BACKGROUND: Maternal malaria is associated with serious adverse pregnancy outcomes. One recommended means of preventing malaria during pregnancy is intermittent preventive therapy (IPTp) with sulfadoxine/pyrimethamine (SP). We sought to identify determinants of preventive use of SP during pregnancy...

Descripción completa

Detalles Bibliográficos
Autores principales: Sangaré, Laura R., Stergachis, Andy, Brentlinger, Paula E., Richardson, Barbra A., Staedke, Sarah G., Kiwuwa, Mpungu S., Weiss, Noel S.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993958/
https://www.ncbi.nlm.nih.gov/pubmed/21124732
http://dx.doi.org/10.1371/journal.pone.0015066
_version_ 1782192867831185408
author Sangaré, Laura R.
Stergachis, Andy
Brentlinger, Paula E.
Richardson, Barbra A.
Staedke, Sarah G.
Kiwuwa, Mpungu S.
Weiss, Noel S.
author_facet Sangaré, Laura R.
Stergachis, Andy
Brentlinger, Paula E.
Richardson, Barbra A.
Staedke, Sarah G.
Kiwuwa, Mpungu S.
Weiss, Noel S.
author_sort Sangaré, Laura R.
collection PubMed
description BACKGROUND: Maternal malaria is associated with serious adverse pregnancy outcomes. One recommended means of preventing malaria during pregnancy is intermittent preventive therapy (IPTp) with sulfadoxine/pyrimethamine (SP). We sought to identify determinants of preventive use of SP during pregnancy among recently pregnant women in Uganda. Additionally, we characterized the timing of and indications for the administration of SP at antenatal care (ANC) visits and missed opportunities for SP administration. METHODOLOGY/PRINCIPAL FINDINGS: Utilizing a population-based random sample, we interviewed 500 women living in Jinja, Uganda who had been pregnant in the past year. Thirty-eight percent (192/500) of women received SP for the treatment of malaria and were excluded from the analysis of IPTp-SP. Of the remaining women, 275 (89.3%) reported at least two ANC visits after the first trimester and had an opportunity to receive IPTp-SP according to the Ugandan guidelines, but only 86 (31.3%) of these women received a full two-dose course of IPTp. The remaining 189 (68.7%) women missed one or more doses of IPTp-SP. Among the 168 women that were offered IPTp, 164 (97.6%) of them took the dose of SP. CONCLUSIONS/SIGNIFICANCE: Use of IPTp in Uganda was found to be far below target levels. Our results suggest that women will take SP for IPTp if it is offered during an ANC visit. Missed opportunities to administer IPTp-SP during ANC were common in our study, suggesting provider-level improvements are needed.
format Text
id pubmed-2993958
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-29939582010-12-01 Determinants of Use of Intermittent Preventive Treatment of Malaria in Pregnancy: Jinja, Uganda Sangaré, Laura R. Stergachis, Andy Brentlinger, Paula E. Richardson, Barbra A. Staedke, Sarah G. Kiwuwa, Mpungu S. Weiss, Noel S. PLoS One Research Article BACKGROUND: Maternal malaria is associated with serious adverse pregnancy outcomes. One recommended means of preventing malaria during pregnancy is intermittent preventive therapy (IPTp) with sulfadoxine/pyrimethamine (SP). We sought to identify determinants of preventive use of SP during pregnancy among recently pregnant women in Uganda. Additionally, we characterized the timing of and indications for the administration of SP at antenatal care (ANC) visits and missed opportunities for SP administration. METHODOLOGY/PRINCIPAL FINDINGS: Utilizing a population-based random sample, we interviewed 500 women living in Jinja, Uganda who had been pregnant in the past year. Thirty-eight percent (192/500) of women received SP for the treatment of malaria and were excluded from the analysis of IPTp-SP. Of the remaining women, 275 (89.3%) reported at least two ANC visits after the first trimester and had an opportunity to receive IPTp-SP according to the Ugandan guidelines, but only 86 (31.3%) of these women received a full two-dose course of IPTp. The remaining 189 (68.7%) women missed one or more doses of IPTp-SP. Among the 168 women that were offered IPTp, 164 (97.6%) of them took the dose of SP. CONCLUSIONS/SIGNIFICANCE: Use of IPTp in Uganda was found to be far below target levels. Our results suggest that women will take SP for IPTp if it is offered during an ANC visit. Missed opportunities to administer IPTp-SP during ANC were common in our study, suggesting provider-level improvements are needed. Public Library of Science 2010-11-29 /pmc/articles/PMC2993958/ /pubmed/21124732 http://dx.doi.org/10.1371/journal.pone.0015066 Text en Sangaré et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Sangaré, Laura R.
Stergachis, Andy
Brentlinger, Paula E.
Richardson, Barbra A.
Staedke, Sarah G.
Kiwuwa, Mpungu S.
Weiss, Noel S.
Determinants of Use of Intermittent Preventive Treatment of Malaria in Pregnancy: Jinja, Uganda
title Determinants of Use of Intermittent Preventive Treatment of Malaria in Pregnancy: Jinja, Uganda
title_full Determinants of Use of Intermittent Preventive Treatment of Malaria in Pregnancy: Jinja, Uganda
title_fullStr Determinants of Use of Intermittent Preventive Treatment of Malaria in Pregnancy: Jinja, Uganda
title_full_unstemmed Determinants of Use of Intermittent Preventive Treatment of Malaria in Pregnancy: Jinja, Uganda
title_short Determinants of Use of Intermittent Preventive Treatment of Malaria in Pregnancy: Jinja, Uganda
title_sort determinants of use of intermittent preventive treatment of malaria in pregnancy: jinja, uganda
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993958/
https://www.ncbi.nlm.nih.gov/pubmed/21124732
http://dx.doi.org/10.1371/journal.pone.0015066
work_keys_str_mv AT sangarelaurar determinantsofuseofintermittentpreventivetreatmentofmalariainpregnancyjinjauganda
AT stergachisandy determinantsofuseofintermittentpreventivetreatmentofmalariainpregnancyjinjauganda
AT brentlingerpaulae determinantsofuseofintermittentpreventivetreatmentofmalariainpregnancyjinjauganda
AT richardsonbarbraa determinantsofuseofintermittentpreventivetreatmentofmalariainpregnancyjinjauganda
AT staedkesarahg determinantsofuseofintermittentpreventivetreatmentofmalariainpregnancyjinjauganda
AT kiwuwampungus determinantsofuseofintermittentpreventivetreatmentofmalariainpregnancyjinjauganda
AT weissnoels determinantsofuseofintermittentpreventivetreatmentofmalariainpregnancyjinjauganda